(C) PLOS One
This story was originally published by PLOS One and is unaltered.
. . . . . . . . . .



Ethnic differences in early onset multimorbidity and associations with health service use, long-term prescribing, years of life lost, and mortality: A cross-sectional study using clustering in the UK  [1]

['Fabiola Eto', 'Wolfson Institute Of Population Health', 'Queen Mary University Of London', 'London', 'United Kingdom', 'Miriam Samuel', 'Rafael Henkin', 'William Harvey Research Institute', 'Meera Mahesh', 'Barts']

Date: 2023-11

These findings emphasise the need to identify, prevent, and manage multimorbidity early in the life course. Our work provides additional insights into the excess burden of early onset multimorbidity in those from socioeconomically deprived and diverse groups who are disproportionately and more severely affected by multimorbidity and highlights the need to ensure healthcare improvements are equitable.

Using linked primary and secondary care data from the Clinical Practice Research Datalink GOLD (CPRD GOLD), we conducted a cross-sectional study of 837,869 individuals with early onset multimorbidity (aged between 16 and 39 years old when the second LTC was recorded) registered with an English general practice between 2010 and 2020. The study population included 777,906 people of White ethnicity (93%), 33,915 people of South Asian ethnicity (4%), and 26,048 people of Black African/Caribbean ethnicity (3%). A total of 204 LTCs were considered. Latent class analysis stratified by ethnicity identified 4 clusters of multimorbidity in White groups and 3 clusters in South Asian and Black groups. We found that early onset multimorbidity was more common among South Asian (59%, 33,915) and Black (56% 26,048) groups compared to the White population (42%, 777,906). Latent class analysis revealed physical and mental health conditions that were common across all ethnic groups (i.e., hypertension, depression, and painful conditions). However, each ethnic group also presented exclusive LTCs and different sociodemographic profiles: In White groups, the cluster with the highest rates/odds of the outcomes was predominantly male (54%, 44,150) and more socioeconomically deprived than the cluster with the lowest rates/odds of the outcomes. On the other hand, South Asian and Black groups were more socioeconomically deprived than White groups, with a consistent deprivation gradient across all multimorbidity clusters. At the end of the study, 4% (34,922) of the White early onset multimorbidity population had died compared to 2% of the South Asian and Black early onset multimorbidity populations (535 and 570, respectively); however, the latter groups died younger and lost more years of life. The 3 ethnic groups each displayed a cluster of individuals with increased rates of primary care consultations, hospitalisations, long-term prescribing, and odds of mortality. Study limitations include the exclusion of individuals with missing ethnicity information, the age of diagnosis not reflecting the actual age of onset, and the exclusion of people from Mixed, Chinese, and other ethnic groups due to insufficient power to investigate associations between multimorbidity and health-related outcomes in these groups.

The population prevalence of multimorbidity (the existence of at least 2 or more long-term conditions [LTCs] in an individual) is increasing among young adults, particularly in minority ethnic groups and individuals living in socioeconomically deprived areas. In this study, we applied a data-driven approach to identify clusters of individuals who had an early onset multimorbidity in an ethnically and socioeconomically diverse population. We identified associations between clusters and a range of health outcomes.

Competing interests: FE receive salary for this work by MRC (MR/S027297/1). SF and RM receive salary contributions for their work on the Genes & Health programme, by a Life Sciences Consortium that includes Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. RM is supported by Barts Charity (MGU0504). RM has received consulting fees from AMGEN unrelated to this work. RHM has received fees from American Center for Psychiatry & Neurology United Arab Emirates, British Association for Psychopharmacology, European College of Neuropsychopharmacology, International Society for Affective Disorders, Janssen, LivaNova, Lundbeck, My Tomorrows, OCM Comunicaziona s.n.c., Pfizer, Qatar International Mental Health Conference, Sunovion, Syntropharma, UK Medical Research Council and Wiley; grant support from National Institute for Health Research Efficacy and Mechanism Evaluation Panel and Health Technology Assessment Panel; and non-financial support from COMPASS Pathways and Magstim. PM is funded by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre, by NIHR AIM AI-MULTIPLY, and by NIHR ADMISSION (MR/V033654/1). NJR is funded by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre, by the NIHR Newcastle In Vitro Diagnostics Co-operative and NIHR AIM AI-MULTIPLY. N.J.R. is also a NIHR Senior Investigator, (Senior Investigator Award) NIHR200168. NJR reports grants from PSORT industrial partners as listed ( http://www.psort.org.uk/ ); other research grants from GSK Stiefel and Novartis. MRB is funded by the National Institute for Health Research (NIHR) AIM AI-MULTIPLY Consortium (NIHR203982). MRB reports research grants from Benevolent AI, Janssen and Novartis. TA is funded by the NIHR Applied Research Collaboration North Thames Award (NIHR 200163). AA is funded by the NIHR (31672 AI-MULTIPLY, 2022-2025). RH is funded by the Health Data Research UK (grant ref: LOND1).

Funding: This work (and salary costs to SF, RM, SH, FE) was supported by MRC (MR/S027297/1). “Multimorbidity clusters, trajectories and genetic risk in British south Asians, 2020-2023”. Link: https://gtr.ukri.org/projects?ref=MR%2FS027297%2F1 . RM is supported by Barts Charity (MGU0504). Additional support for this and related work (SF, MRB, NJR, PM, RHM, RH, AA, MS, FE) is from NIHR 31672 AI-MULTIPLY, 2022-2025, and NIHR 202635 (SF, NJR, MRB, PM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability: The Clinical Practice Research Datalink (CPRD) does not allow the sharing of patient-level data. The structure and format of the CPRD data set is available at: https://cprd . com/sites/default/files/CPRD%20GOLD%20Full %20Data%20Specification%20v2.0_0.pdf. The data that support the findings of this study are available from CPRD and access is subject to approval from an Independent Scientific Advisory Committee (ISAC). The data were used under license for the current study. The list of long-term conditions and respective code lists used in this study are available at: https://github.com/Fabiola-Eto/MULTIPLY-Initiative . The poLCAParallel R package is available at: https://github.com/QMUL/poLCAParallel/releases/tag/v1.1.0 . This research utilised Queen Mary's Apocrita HPC facility, supported by QMUL Research-IT. http://doi.org/10.5281/zenodo.438045 .

In order to address the abovementioned limitations of existing multimorbidity research, the aims of this study were as follows: firstly, to develop and test a consensus-derived, open-access codelist resource for multimorbidity research with an expanded focus on all LTCs that might contribute to multimorbidity, irrespective of prevalence, with a particular ambition that this resource can adequately address ethnic differences in multimorbidity presentations that may be driven by low prevalence but high impact conditions; secondly, to apply a data-driven approach to identify patterns of LTCs in individuals with early onset of multimorbidity in an ethnically and socioeconomically diverse multimorbid population; and thirdly, to assess ethnic differences in the associations between clusters of individuals and 4 clinically meaningful health outcomes: health service utilisation, long-term prescribing, years of life lost (YLL), and mortality.

While multimorbidity is usually defined as the presence of 2 or more LTCs, the majority of multimorbidity research in the UK focuses on a limited set of around 40 highly prevalent LTCs [ 16 – 21 ]. This approach excludes less prevalent or ethnically patterned diseases and is likely to result in a substantial underestimate of the population prevalence of multimorbidity. A recent systematic review also highlighted the variable and poor reporting of multimorbidity and suggested the need for consensus-based, reproducible definitions [ 22 ].

The majority of studies mapping patterns of multimorbidity focus on diseases as the unit of analysis rather than individuals [ 15 ]. However, analysing multimorbidity patterns at an individual level enables a deeper understanding of potentially shared biological and environmental risk factors among specific population groups and understand what similarities they share in terms of sociodemographic profile and what LTCs are the main drivers of increased healthcare service utilisation, long-term prescribing, and mortality.

A comprehensive approach to map patterns of multiple LTCs in an ethnically and socioeconomically diverse population with early onset of multimorbidity is crucial to understand the distinct and shared mechanisms that lead to disease accumulation and enable early intervention and reconfigure services to meet the needs of more vulnerable groups.

People living with multiple LTCs account for the majority of primary care and hospital utilisation and long-term medication use. Systematic reviews from the United Kingdom [ 11 ] and internationally [ 12 ] have shown that health service utilisation and costs tend to increase with each additional condition in a single individual. Nonetheless, medical guidelines are centred on the treatment of individual health conditions and often do not account for interactions between conditions that commonly co-occur [ 13 , 14 ]. Likewise, increasing multimorbidity has been associated with an increased mortality risk, with risk higher still in some ethnic minority groups (Pakistani, Black African, Black Caribbean, and Other Black ethnic groups) compared to the White group [ 10 ].

While many previous studies of multimorbidity have focused on older adults [ 4 , 5 ], few have investigated multimorbidity in younger populations [ 6 , 7 ]. Importantly, recent studies have shown an increasing prevalence of multimorbidity in early adulthood [ 4 , 8 ], particularly in ethnic minority and socially deprived populations [ 8 – 10 ]. Relatedly, there is evidence showing that individuals with socioeconomic vulnerability experience poorer health outcomes, such as lower quality healthcare provision, premature death, and higher mortality rates [ 8 – 10 ].

Prevalence rate ratios were estimated using negative binomial regression models and zero-inflated Poisson models to account for the overdispersion found in the number of consultations and hospitalisations and to deal with the excess of zeros found in long-term prescribing data. For each outcome of interest, the cluster with the lowest frequency of the outcomes was considered the reference group.

Generalised linear models adjusted by age in 2010, sex, and deprivation quintile were estimated to investigate which clusters had higher odds of mortality, greater YLL, and higher health services utilisation over a 10-year interval. Odds ratios were estimated using logistic regression models to investigate cluster differences in the odds of mortality by the end of the fifth and 10th years.

The YLL for each ethnic group and their respective clusters of individuals were estimated using the R library “lillies” [ 34 ], which allows the estimation of YLL according to a given condition (e.g., groups of individuals with a certain characteristic), and the calculation of confidence intervals using bootstrapping technique.

We described the characteristics of people in our population according to their age in 2010, age at onset of multimorbidity, sex, and socioeconomic deprivation. For each of the clusters of individuals identified from the latent class analysis, we described the distribution of the LTCs per cluster as well as the characteristics of the individual in each cluster according to sociodemographic variables, health service utilisation, YLL, and mortality.

Outcomes included health service utilisation, long-term prescribing, YLL, and mortality. All outcomes were captured between 2010 and 2020. Health service utilisation was defined as the number of primary care consultations (defined by the dates of consultation with any primary care clinician and regardless of the type of consultation), and the number of hospitalisations (defined by the discharge dates related to admitted-patient care) recorded between 2010 and 2020. Long-term prescribing was identified as the counts of unique prescriptions per British National Formulary (BNF) subparagraphs [ 32 ], prescribed 3 or more times per year, and it was assessed for the period between 2010 and 2020. Mortality was assessed at the year 5 and 10 after 2010 and was based on the total number of deaths by the end of the respective periods. The YLL were estimated using the remaining average life expectancy after becoming multimorbid and before reaching the average life expectancy at birth of 81 years for the UK population [ 33 ].

For each ethnic group, we tested 2- to 10-class models (where the number of classes represents the number of possible clusters) with a maximum iteration of 1,000 using the poLCAParallel [ 31 ] R package and R-4.2.1. We obtained and compared the fit statistics for each model, which, along with clinical judgement, were used to select the optimal number of latent classes for each ethnic group (see S2 Text for more details on the model selection criteria).

To focus on individuals rather than diseases as the observation in the analysis, we applied latent class analysis to identify groups of people with similar patterns of LTCs accumulation. This approach allowed each LTC to appear in multiple subgroups of individuals, and it is more consistent with clinical experience than other approaches where each LTC could belong to only one cluster at a time. LTCs were identified using all available data in the individual’s electronic health record, spanning from as far back as 1920 through to 2020. The latent class analysis is a person-centred mixture modelling approach that identifies latent or unobserved classes (e.g., subpopulations) within a sample based on their patterns of responses to observed variables (e.g., presence/absence of an LTC) given by the posterior membership probabilities, which inform the probability of an individual belonging to a certain subgroup [ 29 ]. For each latent class (e.g., subgroup of people with similar characteristics), the average latent class probability was estimated, which indicated the probability of the class model accurately predicting class membership for individuals [ 30 ].

To investigate whether the accumulation of LTCs over the life course in people with early onset of multimorbidity differs by ethnicity, we stratified our analysis according to 3 following ethnic groups—White, Black (Black African, Black Caribbean, and Black Other), and South Asian (Indian, Bangladeshi, and Pakistani). Information on self-reported ethnicity was obtained from primary care electronic health records as captured during registration and/or consultation episodes [ 28 ].

Using all data available from the individual’s primary care and secondary care health records, we identified each LTC using the first relevant code ever recorded and calculated the age at diagnosis by subtracting the year of birth from the year of diagnosis. If a condition was never recorded, it was considered absent.

Building on existing literature and previous concerns about the lack of reproducibility in multimorbidity research, we undertook a systematic approach to operationalising this definition of multimorbidity for our study. We searched the literature for definitions of multimorbidity and made comparisons between LTCs included in different studies [ 16 , 17 , 24 – 26 ]. We searched existing online repositories, publications, and supplementary material for previously built codelists. Where multiple codelists were found, we combined all the relevant codes used by the studies to develop a baseline codelist that underwent extensive clinical review. We conducted a clinical consensus exercise to further refine the set of LTCs to be included in our study (see S1 Text for more details). Detailed information on the methods used to curate the codelists, and the codelists themselves, are available in the MULTIPLY-Initiative online repository [ 27 ].

We used the Academy of Medical Sciences definition of multimorbidity [ 1 ], as follows: The coexistence of 2 or more LTCs, each one of which is either (a) a physical noncommunicable disease of long duration, such as cardiovascular disease or cancer; (b) a mental health condition of long duration, such as a mood disorder or dementia; or (c) an infectious disease of long duration, such as HIV or hepatitis C.

From the CPRD GOLD source population, we selected a study population of individuals who met the following inclusion criteria: (i) had at least 2 out of a list of 204 LTCs; (ii) belonged to one of the following ethnic groups: White, South Asian, or Black African/Caribbean; (iii) had a valid date of second LTC diagnosis in order to calculate age at the onset of multimorbidity; and (iv) had early onset of multimorbidity, defined by having the second LTC recorded between the ages of 16 and 39 years. The selection of our source population is illustrated in Fig 1 .

We performed a cross-sectional study using the Clinical Practice Research Datalink GOLD (CPRD GOLD), a large representative English electronic health records database [ 23 ]. We identified a source population of individuals aged 16 years and over, registered with an English general practice between January 1, 2010, and December 31, 2020, whose data met CPRD’s acceptable data quality standards and who had linkage to Hospital Episode Statistics Admitted-Patient Care (HES-APC) data. We also obtained linkage to Office for National Statistics mortality data and area-level deprivation data (Index of Multiple Deprivation (IMD)).

We observed different associations between socioeconomic deprivation and outcomes that further varied by ethnicity. While living in socioeconomically deprived areas was associated with lower rates of primary care consultations for South Asians [PRR = 0.92, 95% CI 0.89 to 0.94] compared to their peers from more affluent areas, it was associated with higher rates for Whites [PRR = 1.03, 95% CI 1.02 to 1.04] living in deprived areas compared to their wealthier peers. However, Whites, South Asians, and Black African/Caribbean living in socioeconomically deprived areas had similarly higher rates of hospitalisations [PRR = 1.14, 95% CI 1.13 to 1.14, PRR = 1.19, 95% CI 1.17 to 1.21, and PRR = 1.38, 95%CI 1.35 to 1.42, respectively] and long-term prescribing [PRR = 1.25, 95% CI 1.25 to 1.26, PRR = 1.20, 95% CI 1.18 to 1.23, and PRR = 1.16, 95% CI 1.12 to 1.20, respectively] compared to their peers in less deprived areas ( Table 3 ). These associations assume that the other covariables in the regression model are held constant.

For the Black population, the cluster with the highest rates/odds of outcomes was led by hypertension, painful conditions, and depression (cluster 3), while the cluster with the lowest rates/odds of outcomes was led by female infertility, male infertility, and menorrhagia (cluster 1) ( Fig 6 ). Compared to people in cluster 1, individuals in cluster 3 had higher rates of primary care consultation [PRR = 1.74, 95% CI 1.67 to 1.81] and long-term prescribing [PRR = 2.34, 95% CI 2.27 to 2.41], but the magnitude of difference was less than that seen in the other ethnic groups. However, individuals in cluster 3 had significantly greater rates of hospitalisation [PRR = 5.47, 95% CI 5.35 to 5.6] and the highest odds of mortality by the end of the year 5 [OR = 17.15, 95% CI 5.39 to 54.55] and 10 [OR = 8.32, 95% CI 5.24 to 13.2]. Individuals in cluster 3 lost an average of 18.0 years of life compared to 1.3 years in cluster 1, consistent with the findings from the South Asian population.

For the South Asian group, the cluster with the highest rates/odds of outcomes was led by painful conditions, hypertension, and depression (cluster 3), while the cluster with the lowest rates/odds of outcomes was led by female infertility, male infertility, and dermatitis (cluster 1) ( Fig 5 ). Individuals in cluster 3 had twice the rate of primary care consultation [PRR = 1.96, 95% CI 1.89 to 2.03], twice the rate of long-term prescribing [PRR = 2.57, 95% CI 2.51 to 2.64], 3 times the rate of hospitalisation [PRR = 3.13, 95% CI 3.06 to 3.19], and 8 and 11 times the odds of mortality by the end of the year 5 and 10 [OR = 8.48, 95% CI 3.06 to 23.51; OR = 10.86, 95% CI 5.71 to 20.66, respectively] compared to people in cluster 1 ( Table 3 ). Individuals in cluster 3 lost an average of 18.5 years of life after becoming multimorbid and before reaching 81 years old compared to an average of 0.8 years of life in cluster 1, an order of magnitude greater than the same comparison in Whites ( Table 2 ).

Compared to individuals in cluster 1, individuals in cluster 4 had over double the rate of primary care consultation, [PRR = 2.14, 95% CI 2.12 to 2.16]; 3 times the rate of long-term prescribing over 10 years [PRR = 3.15, 95% CI 3.13 to 3.17]); 5 times the rate of hospitalisation [PRR = 5.48, 95% CI 5.45 to 5.51]); and between a 6- to 12-fold higher odds of mortality [OR at the year 5 = 5.93, 95% CI 5.2 to 6.76 and OR at year 10 = 12.03, 95% CI 11.03 to 13.13] ( Table 3 ). They also lost an average of 10.6 years of life after becoming multimorbid and before reaching the UK’s life expectancy of 81 years old compared to an average of 0.4 years in cluster 1 ( Table 2 ).

For the White group, the cluster with the highest rates/odds of outcomes was led by hypertension, depression, and painful conditions (cluster 4), while the cluster with the lowest rates/odds of outcomes was led by female infertility, male infertility, and depression (cluster 1) ( Fig 4 ). Those in cluster 4 had a greater median number of LTCs (n = 15, IQR 12 to 20) compared to those in cluster 1 (6, 5 to 9) ( Table 2 ).

The clusters with the lowest rates/odds of the outcomes were relatively homogeneous across all 3 ethnic groups and were used as the reference group in our regression models. The most common LTCs in those clusters across all ethnicities were female infertility and male infertility.

In each of the 3 ethnic groups, the clusters with the highest rates/odds of the outcomes shared 14 of the 20 most prevalent LTCs and shared their 3 leading conditions—hypertension, depression, and painful conditions ( Fig 3 ). However, beyond these similarities, there was variation in the composition of those clusters according to ethnicity: COPD, CHD, hearing loss, and venous or lymphatic disease were prevalent in the White group; allergic rhinitis, iron deficiency anaemia, menorrhagia and polymenorrhoea, migraine, and post-traumatic stress and stress-related disorders were prevalent in South Asian and Black groups; oesophageal ulcer was prevalent conditions in White and South Asian groups, but not in the Black groups; and chronic kidney disease (CKD) was highly prevalent in White and Black groups, but not in the South Asian group ( Fig 3 ). Descriptive sociodemographic characteristics comparisons between the clusters with the highest rates/odds of the outcomes according to ethnic groups can be seen in S1 – S3 Figs.

During the 10-year period (2010 to 2020), South Asian and White groups had a higher median number of primary healthcare consultations per individual (South Asian 80, IQR: 42 to 143; White 75, 36 to 142), while Black groups had the lowest number of primary care consultations in the same period (71, 36 to 127). Similarly, median number of long-term prescriptions between 2010 and 2020 per individual was higher among South Asian (2, 0 to 5) and White groups (2, 0 to 5) compared to Black groups (1, 0 to 4). However, the median number of hospitalisation episodes over the 10-year period was higher for Black groups (3, 1 to 5) compared to White and South Asian groups (2, 1 to 5). People of Black African/Caribbean ethnicity lost more years of life on average (30.8) than those of White (21.1) and South Asian ethnicity (28.0) after developing early onset multimorbidity and before reaching the average of 81 years old [ 33 ].

Fig 2 shows the distribution of the top 20 most prevalent LTCs across all 3 ethnic groups and the proportion of clusters where each condition appears. Anxiety or phobia, asthma, constipation, depression, dermatitis, enthesopathy, gastro-oesophageal reflux, obesity, and painful conditions were highly prevalent LTCs that occurred in all clusters across the 3 ethnic groups. Eight highly prevalent LTCs appeared exclusively in the White population (alcohol dependence and related disease, chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD), hearing loss, sinusitis, psychoactive substance misuse, urinary incontinence, and venous or lymphatic disease); 4 highly prevalent LTCs appeared exclusively in the South Asian population (polycystic ovarian syndrome, seborrheic dermatitis, thyroid disease, and urticaria); and schizophrenia was highly prevalent in the Black population only (Figs 2 and 3 ).

After evaluating the fit statistics for the latent class models ( S2 Text ) and upon clinical judgement, we identified 4 clusters of individuals in the White population and 3 clusters of individuals in the South Asian and Black populations. Although we included all 204 LTCs in the latent class models, throughout the paper, we discuss only the 20 most prevalent conditions in each cluster for clarity. The prevalence for all 204 LTCs per cluster and ethnicity can be found in the S1 and S2 Tables, respectively.

The median number of LTCs was higher in the White population (median = 6, IQR 4 to 10), compared to the South Asian (5, 3 to 8) and the Black populations (5, 3 to 8). By the end of the study, 4% (N = 36,027) of the total early onset multimorbid population had died, 4% of White, 2% of South Asian, and 2% of Black African/Caribbean. However, South Asian and Black groups died at a younger age than White groups (median age = 52, 48, and 61 years, respectively) ( Table 1 ).

From the total multimorbid population, we identified 837,869 individuals with early onset multimorbidity (16 to 39 years at onset), of whom 777,906 (93%) were White, 33,915 (4%) were South Asian, and 26,048 (3%) were Black African/Caribbean. Early onset multimorbidity was the most common form of multimorbidity among South Asian and Black groups (59%, n = 33,915 and 56%, n = 26,048, respectively) in contrast with the White population (42%, n = 777,906). The median age at multimorbidity onset was 30 years for South Asian, 31 years for Black, and 29 years for White ethnic groups. Women comprised the majority of multimorbid individuals in the South Asian and Black populations (70% and 73%, respectively, compared to 65% in the White population). The early onset multimorbid South Asian and Black populations were mostly from greater socioeconomically deprived areas (28% and 39%, respectively, belonged to the most deprived IMD quintile) compared to the White population where 21% belonged to the least deprived IMD quintile.

From a total of 3,984,233 people in the CPRD GOLD aged 16 years and over between 2010 and 2020, 2,814,507 individuals (70.6%) had at least one of the 204 LTCs ever recorded in their electronic health record. We identified our multimorbid population (n = 1,961,888, 69.7%) as those who had developed 2 or more of the 204 LTCs at age 16 years or above, and who belonged to one of the 3 ethnic groups under investigation ( Fig 1 ).

Discussion

Our findings show that in a large, multimorbid UK population, approximately 40% developed multimorbidity early (aged 16 to 39 years). Black and South Asian populations were more likely to become multimorbid early as compared to Whites. We built on these findings to demonstrate the impact of early onset multimorbidity using measures of healthcare utilisation (primary care consultations, hospitalisation), long-term prescription use, mortality, and YLL. In doing so, we have demonstrated for the first time that South Asian and Black groups with early onset multimorbidity died younger and lost more years of life once they become multimorbid compared to the White group. Although it is well established that multimorbidity increases with age [4,7,35], we show that multimorbidity is highly prevalent in younger populations and disproportionately affects minority ethnic and socially deprived groups, highlighting the need for early interventions to prevent and manage multimorbidity in those populations.

To our knowledge, this is the first study to investigate early onset of multimorbidity and its variation by ethnicity in a large UK population-based sample. By applying a data-driven approach across multiple LTCs, and combining this with measures of healthcare utilisation, mortality, and YLL, we have built new understanding of the burden and impact of early onset multimorbidity at a population scale. Our findings provide important justification to improve the prevention, recognition, and management of multimorbidity in young and diverse populations.

Our observation that the Black population with early onset multimorbidity has the lowest rate of primary care consultations and long-term prescriptions but higher rates of hospitalisation and mortality compared to South Asian and White groups suggests that a lack of routine care could underlie these worse outcomes. However, similar to the Black population, South Asian groups had higher mortality and YLL than the White group yet had the highest rate of primary care consultations across all groups. These findings highlight the importance of understanding the complex relationship between ethnicity, access to and uptake of healthcare in order to improve outcomes from multimorbidity. Previous reports [36–41] have suggested that structural racism may play a role in explaining poorer health outcomes for certain groups within the UK—highlighting less positive experiences of care, insufficient support from local services, poorer treatment outcomes, and a lack of confidence in self-management of multimorbidity among minority ethnic groups compared to White groups [36–41], which is likely to contribute to inequalities in the effective identification and management of multimorbidity, resulting in higher mortality and YLL.

We highlighted important differences in outcomes within ethnic groups associated with deprivation. South Asian people living in areas of high socioeconomic deprivation had lower rates of primary care consultations, but higher rates of hospitalisation and long-term prescribing than their peers living in more affluent areas. Black groups living in areas of high socioeconomic deprivation had higher rates of hospitalisation and long-term prescribing than their peers living in more affluent areas. In contrast, White groups with high socioeconomic deprivation had higher rates of consultation, hospitalisation, and long-term prescribing than their peers from affluent areas. Previous studies show that people with multimorbidity living in more deprived areas may receive poorer quality healthcare represented by shorter consultation times, poorer patient-centeredness, and lower perceived GP empathy compared to those living in more affluent areas [36,42]. These findings demonstrate the intersecting influences of ethnicity and socioeconomic deprivation that require action from clinical and public health systems to tackle upstream determinants of health that contribute to these stark inequalities and poor outcomes from multimorbidity.

Mortality for Black individuals in the cluster led by hypertension, painful conditions, and depression (cluster 3) was greater by the end of year 5 than by the end of year 10. This may suggest a survivor effect in which individuals with more severe health conditions do not reach older ages. Differences in socioeconomic deprivation did not explain the mortality differential between clusters of South Asian and Black individuals. This may be due to the similar distribution of socioeconomic deprivation across all clusters in those ethnic groups, which was different from the White group, where those in the cluster with highest rates/odds of the outcomes had greater levels of socioeconomic deprivation than those in the cluster with lowest rates/odds of the outcomes.

Our comprehensive inclusion of 204 LTCs and the application of data-driven approaches allowed us to generate unique insights into the early onset of multimorbidity, and the contribution of conditions with varied prevalence, e.g., by ethnicity, which are excluded from most other multimorbidity studies (e.g., sickle cell disease, chronic viral hepatitis, polycystic ovarian syndrome, thalassemia). By linking clusters of LTCs to clinically important outcomes, we were able to identify clusters of multimorbid individuals with the highest frequency of primary and secondary care consultations, long-term prescribing, greater YLL, and greater mortality. These clusters in each ethnic group showed some similarities: They largely comprised older people living in areas of high socioeconomic deprivation. Common to all clusters with the highest rates/odds of the outcomes were a range of high prevalence physical and mental health conditions, including hypertension, depression, painful conditions, type 2 diabetes, and anxiety. However, ethnic differences between them were observed. The cluster with the highest rates/odds of the outcomes in White individuals comprised predominantly men and included conditions not observed in similar clusters in South Asian and Black groups: COPD, CHD, CKD, hearing loss, and venous or lymphatic disease. In contrast, the clusters with the highest rates/odds of the outcomes in Black and South Asian groups were predominantly comprised of women and included conditions not seen in Whites: allergic rhinitis, iron deficiency anaemia, menorrhagia and polymenorrhoea, migraine, and post-traumatic stress disorder.

Differences in health service use and long-term prescribing associated with multimorbidity may be related to the combination of conditions that lead one to seek healthcare as well as having potentially manageable and resolvable conditions. In addition, individuals with a given LTC are more likely to seek healthcare services, which may result in multiple LTCs being detected over time [12]. Furthermore, the number of LTCs identified may be related to the duration of an individual’s data linkage (and, therefore, follow-up time) length of the individuals’ follow-ups and age, as individuals with longer follow-up time and older ages have had time and opportunity to have their health-related conditions detected.

Guidelines in the UK that address and manage multimorbidity do not yet include guidance for managing the accumulation of LTCs in individuals with an early onset, nor bring guidance on targeted healthcare for minoritized ethnic groups or socioeconomically deprived groups at high premature risk for poorer health outcomes such as hospitalisation and premature mortality [43]. Public health policies that aim to reduce multimorbidity should be applied in younger populations and, although universal, should increase targeting towards minority groups and the more socioeconomically disadvantaged population.

[END]
---
[1] Url: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004300

Published and (C) by PLOS One
Content appears here under this condition or license: Creative Commons - Attribution BY 4.0.

via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/plosone/

You are viewing proxied material from magical.fish. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.